IGF1R and cancer: Recent evidence has shown that Vorinostat can modulate the IGF-IR signaling pathway and IGF-I promoter activity in endometrial type-I and –II cancers [13], however, the pro-apoptotic activity of this HDACi proved insensitive to a blocking anti-IGF-IR monoclonal antibody.